Table 4.
The pooled diagnostic performance for 18F-FACBC (independently from the clinical setting and site).
| Meta-Analysis Results | Patient-Based Analysis (95% CI) | Region-Based Analysis (PB) (95% CI) | Region-Based Analysis (ex-PB) (95% CI) | |||
|---|---|---|---|---|---|---|
| Value | I2 | Value | I2 | Value | I2 | |
| Pooled sensitivity, % | 86.3% (79.6–91.4%) | 78.6% | 90.4% (84.8–94.4%) | 22.1% | 76.5% (66–85%) | 87.3% |
| Pooled specificity, % | 75.9% (66.9–83.5%) | 88.7% | 45.1% (33.2–57.3%) | 63.3% | 88.9% (73.9–96.9%) | 78.7% |
| DOR | 16.453 (5.241–51.646) | 29.9% | 8.026 (3.841–16.769) | 3.5% | 24.820 (3.777–163.12) | 36% |
| LR+ | 4.557 (1.685–12.324) | 72.9% | 1.598 (1.088–2.349) | 70% | 6.024 (0.568–63.943) | 85.6% |
| LR− | 0.337 (0.166–0.681) | 63.6% | 0.221 (0.130–0.375) | 0% | 0.251 (0.058–1.090) | 71.6% |
PB = prostatic bed; PPV = positive predictive value; NPV = negative predictive value; DOR = diagnostic odds ratio; LR = likelihood ratio; IC = interval of confidence; I2 = inconsistency.